CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Therapeutic Conventional Surgeryprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02437851
NCT02437851Phase 2Completed
CompareCT.gov

A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons

AIDS Malignancy Consortium·interventional·Posted May 8, 2015·Updated Apr 20, 2026

In Brief

A Phase 2 clinical trial evaluating Therapeutic Conventional Surgery for Anal Squamous Cell Carcinoma and 3 related conditions. Completed, enrolled 16 participants across 5 sites.

Detailed Summary

This phase II trial studies surgery in treating patients with anal canal or perianal cancer that is small and has not spread deeply into the tissues and human immunodeficiency virus (HIV) infection. Local surgery may be a safer treatment with fewer side effects than bigger surgery or radiation and chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnal Squamous Cell Carcinoma, HIV Infection, Stage 0 Anal Canal Cancer, Stage I Anal Canal Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), The Emmes Company, LLC, AIDS and Cancer Specimen Resource, University of Arkansas

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 8, 2015
Enrollment StartApr 1, 2015
Primary CompletionApr 15, 2026
TodayJul 2, 2026
Enrollment to primary: 11.0 yearsPosted 11.2 years ago

Interventions

Therapeutic Conventional Surgeryprocedure

Undergo surgery to remove anal or perianal cancer (SISCCA)